Obtain a Good Blood Glucose Control With the Paradigm Real Time System (RTD)
The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2006 by Medtronic.
Recruitment status was Recruiting
Recruitment status was Recruiting
Sponsor:
Medtronic
Information provided by:
Medtronic
ClinicalTrials.gov Identifier:
NCT00441129
First received: February 27, 2007
Last updated: March 5, 2007
Last verified: December 2006
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
. PRIMARY ENDPOINT
The primary endpoint will be the change from baseline (Visit 3) to 6 months (Visit 6) of centrally measured HbA1c
SECONDARY ENDPOINTS
- Change from baseline in mean blood glucose value calculated from CGMS recordings.
- Change from baseline in occurrence of hyperglycemia above 190 mg/dl .
- Change from baseline in occurrence of hypoglycemia below 70 mg/dl 4. Change from baseline of insulin doses.
5. Total daily use of insulin. 6. % of daily use of insulin as basal rate. 7. % of daily use of insulin as bolus. 8. Patient Satisfaction questionnaire. 9. Health economic questionnaire. 10. Quality of life questionnaire
| Condition | Intervention | Phase |
|---|---|---|
|
Type 1 Diabetes |
Device: Minimed paradigm Real Time Sytem |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | To Assess Whether Type 1 Diabetic Patients Treated With M D I and in Poor Metabolic Control Can Improve Using the Paradigm® Real Time System Compared to Self-Monitoring Blood Glucose and Continuous Subcutaneous Insulin Infusion |
Resource links provided by NLM:
Genetics Home Reference related topics:
type 1 diabetes
MedlinePlus related topics:
Blood Sugar
Diabetes
Diabetes Medicines
Diabetes Type 1
Hyperglycemia
Hypoglycemia
Drug Information available for:
Dextrose
U.S. FDA Resources
Further study details as provided by Medtronic:
Primary Outcome Measures:
- change from baseline (Visit 3) to 6 months (Visit 6) of centrally measured HbA1c
Secondary Outcome Measures:
- Change from baseline in mean blood glucose value calculated from CGMS recordings.
- Change from baseline in occurrence of hyperglycemia above 190 mg/dl expressed as Area Under the Curve (high) above 190 mg/dl (10.5 mmol/l) calculated from CGMS recordings.
- Change from baseline in occurrence of hypoglycemia below 70 mg/dl (3.9 mmol/l) expressed as Area Under the Curve (low) below 70 mg/dl calculated from CGMS recordings.
- Change from baseline of insulin doses.
- Total daily use of insulin.
- % of daily use of insulin as basal rate.
- % of daily use of insulin as bolus.
- Patient Satisfaction questionnaire.
- Health economic questionnaire.
- Quality of life questionnaire
| Estimated Enrollment: | 120 |
| Study Start Date: | June 2006 |
| Estimated Study Completion Date: | October 2007 |
The long-term clinical benefit of tight glycemic control in people with diabetes is well known . HbA1c generally assesses the average/long term quality of glycemic control, it has been clearly demonstrated that a target of HbA1c at 7.0% or less has benefits for diabetic patients
Eligibility| Ages Eligible for Study: | 2 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Patient has signed informed consent form prior to study entry.
- Patients have been diagnosed with Type 1 DM at least 12 months prior to inclusion.
- Patients should have been received diabetes care from the investigator of each center at least 3 months prior to inclusion.
- Patients have been treated with multiple daily injections and use rapid Insulin Analog for their meal prior to study entry.
- Have an HbA1c value ≥ 8 %.
- Pediatric patients must be aged between 2 and 18 years old and adult patients be aged between 19 and 65 years old.
- Patients must perform at least 3 self-monitoring blood glucose finger-sticks daily.
- Patients from PRT group must be willing to wear sensors and transmitter connected to the pump Paradigm® Real-Time for up to 24 weeks and to change sensors, insulin infusion sets and reservoirs every 3 days (~60 times during the study period ).
- Patients from CSII group must be willing to wear an insulin pump, change insulin infusion sets, and reservoirs every 3 days (~60 times during the study period ).
- Patient is required to use the Paradigm® Real-Time system at least 70% of the time during the study period.
- Patients in both groups are required to wear at the beginning and the end of the study a CGMS for 3 days. and to perform 6 self-monitoring blood glucose finger-sticks daily during the 3 days.
- Patients must be willing to undergo all study procedures, to receive a technical training to understand how to use the Paradigm® Real-Time System or the Insulin Pump depending of the randomization.
- Patients must agree to receive a training on how to adapt their insulin doses to their meals, how to calculate and apply corrective treatment.
Exclusion Criteria:
- Hearing or vision impairment so that alarms cannot be recognized.
- Alcohol or drug abuses other than nicotine.
- Allergy to sensor or components of the sensor.
- Allergy to insulin infusion set or components of the insulin infusion set.
- Patient is pregnant or of child-bearing potential during the study.
- Patient does not have a reliable support person or the patient is unwilling to comply with the provisions of the protocol.
- Patients suffering from cancer, heart failure, kidney disease and other chronic debilitating conditions.
- Patients participating in other device or drug studies will be excluded.
- Patients may participate in this study only once.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00441129
Contacts
| Contact: Elisabeth Andrieu, Clin Manag | +33689719056 | elisabeth.andrieu@medtronic.com |
| Contact: Benedicte Florentin, cust relation | +33155386020 | benedicte.florentin@medtronic.com |
Locations
| France | |
| CHU Côte de Nacre | Recruiting |
| Caen, France, 14000 | |
| Contact: Yves Reznick, Professor | |
| Sub-Investigator: Yves Reznick, Professor | |
| Hôpital Jeanne D'Arc | Recruiting |
| Dommartin les Touls, France, 54202 | |
| Contact: Bruno Guerci, Professor | |
| Sub-Investigator: Bruno Guerci, Professor | |
| Hôpital Universitaire Debrousse | Recruiting |
| Lyon, France, 69322 | |
| Contact: Marc Nicolino, Professor | |
| Sub-Investigator: Marc Nicolino, Professor | |
| Hôpital Sainte Marguerite | Recruiting |
| Marseille, France, 13009 | |
| Contact: Denis Raccah, Professor | |
| Principal Investigator: Denis Raccah, Professor | |
| CH La Peyronie | Recruiting |
| Montpellier, France, 34295 | |
| Contact: Eric Renard, Professor | |
| Sub-Investigator: Eric Renard, Professor | |
| American Memorial Hospital | Recruiting |
| Reims, France, 51092 | |
| Contact: Veronique Sulmont, Doctor | |
| Sub-Investigator: Veronique Sulmon | |
| Hôpitaux Universitaires de Strasbourg | Not yet recruiting |
| Strasbourg, France, 67091 | |
| Contact: Nathalie Jeandidier, Professor | |
| Sub-Investigator: Nathalie Jeandidier, Professor | |
| CHU Rangueil | Recruiting |
| Toulouse, France, 31054 | |
| Contact: Helene Hanaire, Professor | |
| Sub-Investigator: Helene Hanaire, Professor | |
Sponsors and Collaborators
Medtronic
Investigators
| Principal Investigator: | denis Raccah, professor | DCCT Group, Effect of Intensive Treatment of diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. NJEM 1993; 329/977-986 |
More Information
No publications provided by Medtronic
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| ClinicalTrials.gov Identifier: | NCT00441129 History of Changes |
| Other Study ID Numbers: | 186 |
| Study First Received: | February 27, 2007 |
| Last Updated: | March 5, 2007 |
| Health Authority: | France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis) |
Keywords provided by Medtronic:
|
Improvement of the blood glucose control |
Additional relevant MeSH terms:
|
Diabetes Mellitus, Type 1 Diabetes Mellitus Glucose Metabolism Disorders Metabolic Diseases |
Endocrine System Diseases Autoimmune Diseases Immune System Diseases |
ClinicalTrials.gov processed this record on June 17, 2013